News

Eucure Biopharma Announces Breakthrough Phase I Results for Anti-CTLA-4 Therapy in Combination with Junshi Biosciences’ Anti-PD-1

BOSTON and BEIJING, March 22, 2021 /PRNewswire/ -- Eucure Biopharma, a subsidiary of Biocytogen focused on developing proprietary immuno-oncology antibodies, announced that its anti-CTLA-4 antibody (YH001), in combination with Junshi…

Read more
Biocytogen announces acquisition of a third Beacon Optofluidic system

BOSTON, Feb. 25, 2021 /PRNewswire/ -- Biocytogen, a company dedicated to accelerating therapeutic antibody discovery, has announced the acquisition of a third Beacon Optofluidic system. The new instrument,…

Read more
Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences’ Toripalimab

BOSTON and BEIJING, Feb. 3, 2021 /PRNewswire/ -- Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with…

Read more
Biocytogen and LiberoThera Enter into Strategic Collaboration Agreement

Beijing, China and Tokyo, Japan, February 1st, 2021 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) and LiberoThera Co.,Ltd (“LiberoThera”) announced today that they have entered into…

Read more
Biocytogen Subsidiary Eucure Biopharma Reports First Patient Enrolled in anti-CTLA4 Phase I Trial in China

BOSTON and BEIJING, Jan. 26, 2021 /PRNewswire/ -- Eucure Biopharma, a subsidiary of Biocytogen, announced the first patient enrollment for a Phase I clinical trial in China to evaluate the safety, tolerability,…

Read more
Beijing Biocytogen Company Name Change Annuncement

Effective December 29th, 2020, our parent company name has officially changed from Beijing Biocytogen Co., Ltd. to Biocytogen Pharmaceuticals (Beijing) Co., Ltd. There is no…

Read more
Biocytogen Enters into RenMab™/RenLite™ Licensing Agreement with Xencor

Xencor to use RenLite™ Fully Human Antibody Mouse Platform to discover novel antibody drugs WAKEFIELD, Mass. and BEIJING, Dec. 7, 2020 /PRNewswire/--Beijing Biocytogen Co., Ltd. , Biocytogen Boston…

Read more
Biocytogen Teams With Ina Research To Boost Presence In Japan

Beijing, China and Nagano, Japan; November 30, 2020-Beijing Biocytogen Co., Ltd. (hereinafter “Biocytogen”) announced today that it has entered into a commercial agency agreement with…

Read more
Festival of Biologics Basel 2020

Therapeutic Antibody Hit Generation Using Fully Human Antibody Transgenic Mice RenMab™ and RenLite™ Speaker: Qingcong Lin, CEO of Biocytogen Boston Corp Time: 1:30pm GMT/8:30am ET,…

Read more
Immuno-Oncology Summit Virtual Summit 2020

About the Immuno-Oncology Summit Over the past 8 years, CHI's Immuno-Oncology Summit has become the leading annual meeting focusing on the latest applied research, providing…

Read more
Back to top